Noggin hFc Chimera, Mouse
| $340.00 | |
| Z06283-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $340.00 | |
| Z06283-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity | > 90% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 49.83 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Measured by its ability to inhibit BMP-4-induced alkaline phosphataseproduction by ATDC5 mouse chondrogenic cells. The ED for this effect is 10 - 80 ng/ml in the presence of 50 ng/mL of Recombinant Human BMP-4. »
The purity of Noggin hFc Chimera, Mouse is greater than 90% as determined by SEC-HPLC. »
Noggin hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 90%. »
| Target Background | Noggin is an antagonist of bone morphogenetic proteins (BMP), being indispensable for certain developmental events.Noggin expression positively correlated with EGFR expression in both GC cell line models and The Cancer Genome Atlas human GC cohort. Targeting EGFR and its downstream pathways diminished cell proliferation which was promoted by Noggin. Noggin promotes the proliferation of GC cells by upregulating EGFR and enhancing a vicious circle formed by β‑catenin, EGFR, ERK and Akt. |
| Synonyms | Noggin; NOG; SYM1; SYNS1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.